Medplus Health Services Ltd
- Market Cap ₹ 9,109 Cr.
- Current Price ₹ 762
- High / Low ₹ 813 / 598
- Stock P/E 303
- Book Value ₹ 101
- Dividend Yield 0.00 %
- ROCE 1.23 %
- ROE 0.82 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 41.5% CAGR over last 5 years
- Company's working capital requirements have reduced from 545 days to 50.0 days
Cons
- Stock is trading at 7.53 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has a low return on equity of 0.65% over last 3 years.
- Promoters have pledged 54.2% of their holding.
- Promoter holding has decreased over last 3 years: -56.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Retail Industry: Trading
Part of BSE 400 MidSmallCap Index Nifty Total Market Nifty Microcap 250 BSE SmallCap BSE 250 SmallCap Index
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|
2 | 2 | 2 | 9 | 10 | 61 | 68 | 146 | 214 | 467 | 631 | |
6 | 7 | 4 | 14 | 13 | 86 | 77 | 142 | 208 | 435 | 572 | |
Operating Profit | -3 | -5 | -2 | -5 | -3 | -25 | -9 | 3 | 6 | 32 | 59 |
OPM % | -137% | -225% | -89% | -52% | -36% | -41% | -13% | 2% | 3% | 7% | 9% |
-1 | 1 | 0 | 1 | 1 | 2 | 2 | 10 | 23 | 7 | 8 | |
Interest | 1 | 0 | 0 | 12 | 0 | 0 | 1 | 3 | 7 | 8 | 8 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 15 | 24 | 27 |
Profit before tax | -5 | -4 | -2 | -16 | -3 | -24 | -9 | 6 | 8 | 7 | 32 |
Tax % | 0% | 0% | 0% | 0% | 0% | 2% | 0% | 0% | 27% | -36% | |
-5 | -4 | -2 | -16 | -3 | -25 | -9 | 6 | 6 | 10 | 30 | |
EPS in Rs | -292.30 | -241.71 | -109.61 | -793.71 | -126.23 | -1,220.91 | -186.95 | 0.47 | 0.46 | 0.80 | 2.52 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 118% |
3 Years: | 90% |
TTM: | 100% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 42% |
3 Years: | 46% |
TTM: | 983% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -3% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 0% |
3 Years: | 1% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.17 | 0.17 | 0.17 | 0.19 | 0.19 | 0.19 | 0.45 | 24 | 24 | 24 | 24 |
Reserves | 126 | 108 | 88 | 185 | 185 | 395 | 517 | 1,089 | 1,117 | 1,149 | 1,186 |
55 | 55 | 55 | 0 | 0 | 3 | 7 | 44 | 86 | 89 | 86 | |
6 | 21 | 39 | 3 | 6 | 17 | 24 | 30 | 45 | 51 | 49 | |
Total Liabilities | 187 | 185 | 183 | 189 | 192 | 415 | 548 | 1,187 | 1,272 | 1,312 | 1,346 |
1 | 1 | 0 | 0 | 0 | 7 | 23 | 85 | 179 | 192 | 181 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 16 | 18 | 0 | 2 |
Investments | 153 | 177 | 177 | 181 | 186 | 381 | 408 | 418 | 917 | 930 | 926 |
34 | 6 | 5 | 8 | 5 | 26 | 115 | 668 | 157 | 190 | 237 | |
Total Assets | 187 | 185 | 183 | 189 | 192 | 415 | 548 | 1,187 | 1,272 | 1,312 | 1,346 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
-5 | -4 | -2 | -1 | -1 | -0 | -6 | -18 | 11 | 8 | |
-11 | -24 | 0 | -2 | -3 | -194 | -15 | -636 | 32 | -24 | |
46 | 0 | 0 | 7 | 0 | 204 | 97 | 569 | -8 | -6 | |
Net Cash Flow | 30 | -28 | -1 | 4 | -4 | 10 | 76 | -86 | 35 | -23 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 32 | 29 | 14 | 22 | 80 | 51 | 62 | 53 | 64 | 51 |
Inventory Days | 33 | 35 | 12 | 16 | 15 | |||||
Days Payable | 9 | 17 | 17 | 30 | 19 | |||||
Cash Conversion Cycle | 32 | 29 | 14 | 22 | 80 | 75 | 79 | 48 | 50 | 47 |
Working Capital Days | -78 | -72 | -130 | -97 | -145 | -11 | -16 | 1,554 | 30 | 50 |
ROCE % | -2% | -1% | -2% | -1% | -8% | -2% | 1% | 1% | 1% |
Documents
Announcements
-
Intimation Under Regulation 30 Read With Schedule III Of SEBI (LODR) Regulations, 2015
55m - Suspension of drug license for four days.
-
Intimation Under Regulation 30 Read With Schedule III Of SEBI (LODR) Regulations 2015
1d - Optival Health Solutions received drug license suspension.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
25 Nov - Schedule of Analyst/Investor meeting on November 26, 2024.
-
Disclosure Pursuant To Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
25 Nov - Disclosure of shareholding change by SBI Mutual Fund.
-
Intimation Under Regulation 30 Read With Schedule III Of SEBI (LODR) Regulations, 2015
24 Nov - Suspension of drug license for Mangalore store.
Annual reports
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
India's Leading Pharmacy Company[1][2]
MedPlus is the 2nd largest pharmacy retailer in India, with 4,552 stores across 12 states and 1 union territory as of Q2 FY25. These stores are strategically distributed to maintain a high presence in metro, tier-one, and tier-two cities.
The stores increased with 108 net new stores added in Q2 FY2025, of which 71 were in Tier-2 and Tier-3 cities[3]